{"id":"cov155","safety":{"commonSideEffects":[{"rate":null,"effect":"Increased heart rate"},{"rate":null,"effect":"Elevated blood pressure"},{"rate":null,"effect":"Insomnia"},{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Dry mouth"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"By blocking the reuptake of norepinephrine at the presynaptic neuron, COV155 increases norepinephrine availability in synaptic spaces, enhancing noradrenergic neurotransmission. This mechanism is intended to improve attention, focus, and other cognitive or behavioral symptoms in conditions where noradrenergic dysfunction is implicated.","oneSentence":"COV155 is a selective norepinephrine reuptake inhibitor that increases norepinephrine levels in the central nervous system.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:07:53.128Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Attention-deficit/hyperactivity disorder (ADHD)"}]},"trialDetails":[{"nctId":"NCT02561741","phase":"PHASE1","title":"Pharmacokinetic, Bioavailability, and Safety Study of COV155 Administered in Healthy Subjects Under Fed and Fasted Conditions","status":"COMPLETED","sponsor":"Mallinckrodt","startDate":"2012-12","conditions":"Pharmacokinetics","enrollment":30},{"nctId":"NCT01743625","phase":"PHASE3","title":"Safety and Efficacy Study of COV155 for Post-operative Bunionectomy Pain","status":"COMPLETED","sponsor":"Mallinckrodt","startDate":"2012-11","conditions":"Pain, Postoperative, Bunion","enrollment":406},{"nctId":"NCT02561650","phase":"PHASE1","title":"Pharmacokinetic, Bioavailability, and Safety Study of COV155 Administered in Healthy Subjects Under Fed and Fasted Conditions","status":"COMPLETED","sponsor":"Mallinckrodt","startDate":"2011-12","conditions":"Pharmacokinetics","enrollment":48},{"nctId":"NCT01722864","phase":"PHASE3","title":"Open Label Safety and Tolerability Study of COV155 in Subjects With Osteoarthritis (OA) or Chronic Low Back Pain (CLBP)","status":"COMPLETED","sponsor":"Mallinckrodt","startDate":"2012-11","conditions":"Osteoarthritis, Knee, Osteoarthritis, Hip, Chronic Low Back Pain","enrollment":153}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["MNK155"],"phase":"phase_3","status":"active","brandName":"COV155","genericName":"COV155","companyName":"Mallinckrodt","companyId":"mallinckrodt","modality":"Small molecule","firstApprovalDate":"","aiSummary":"COV155 is a selective norepinephrine reuptake inhibitor that increases norepinephrine levels in the central nervous system. Used for Attention-deficit/hyperactivity disorder (ADHD).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}